Comorbid amyloid-β pathology affects clinical and imaging features in VCD

Jolien F Leijenaar; Colin Groot; Carole H Sudre; David Bergeron; Anna E Leeuwis; M Jorge Cardoso; Ferran Prados Carrasco; Robert Laforce; Frederik Barkhof; Wiesje M van der Flier; Philip Scheltens; Niels D Prins; Rik Ossenkoppele

doi:https://doi.org/10.1016/j.jalz.2019.08.190

Comorbid amyloid-β pathology affects clinical and imaging features in VCD

Jolien F Leijenaar, Colin Groot, Carole H Sudre, David Bergeron, Anna E Leeuwis, M Jorge Cardoso, Ferran Prados Carrasco, Robert Laforce, Frederik Barkhof, Wiesje M van der Flier, Philip Scheltens, Niels D Prins, Rik Ossenkoppele

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

INTRODUCTION: To date, the clinical relevance of comorbid amyloid-β (Aβ) pathology in patients with vascular cognitive disorders (VCD) is largely unknown.

METHODS: We included 218 VCD patients with available cerebrospinal fluid Aβ42 levels. Patients were divided into Aβ+ mild-VCD (n = 84), Aβ- mild-VCD (n = 68), Aβ+ major-VCD (n = 31), and Aβ- major-VCD (n = 35). We measured depression with the Geriatric Depression Scale, cognition with a neuropsychological test battery and derived white matter hyperintensities (WMH) and gray matter atrophy from MRI.

RESULTS: Aβ- patients showed more depressive symptoms than Aβ+. In the major-VCD group, Aβ- patients performed worse on attention (P = .02) and executive functioning (P = .008) than Aβ+. We found no cognitive differences in patients with mild VCD. In the mild-VCD group, Aβ- patients had more WMH than Aβ+ patients, whereas conversely, in the major-VCD group, Aβ+ patients had more WMH. Atrophy patterns did not differ between Aβ+ and Aβ- VCD group.

DISCUSSION: Comorbid Aβ pathology affects the manifestation of VCD, but effects differ by severity of VCD.

Original language	English
Pages (from-to)	354-364
Number of pages	11
Journal	Alzheimers & Dementia
Volume	16
Issue number	2
Early online date	27 Nov 2019
DOIs	https://doi.org/10.1016/j.jalz.2019.08.190
Publication status	Published - 1 Feb 2020

Keywords

Amyloid-β
Cognition
Gray matter atrophy
MRI
Vascular cognitive disorders
Vascular dementia
White matter hyperintensities

Access to Document

https://doi.org/10.1016/j.jalz.2019.08.190

Cite this

@article{3518ae03ef39454091d914be8f560496,

title = "Comorbid amyloid-β pathology affects clinical and imaging features in VCD",

abstract = "INTRODUCTION: To date, the clinical relevance of comorbid amyloid-β (Aβ) pathology in patients with vascular cognitive disorders (VCD) is largely unknown.METHODS: We included 218 VCD patients with available cerebrospinal fluid Aβ42 levels. Patients were divided into Aβ+ mild-VCD (n = 84), Aβ- mild-VCD (n = 68), Aβ+ major-VCD (n = 31), and Aβ- major-VCD (n = 35). We measured depression with the Geriatric Depression Scale, cognition with a neuropsychological test battery and derived white matter hyperintensities (WMH) and gray matter atrophy from MRI.RESULTS: Aβ- patients showed more depressive symptoms than Aβ+. In the major-VCD group, Aβ- patients performed worse on attention (P = .02) and executive functioning (P = .008) than Aβ+. We found no cognitive differences in patients with mild VCD. In the mild-VCD group, Aβ- patients had more WMH than Aβ+ patients, whereas conversely, in the major-VCD group, Aβ+ patients had more WMH. Atrophy patterns did not differ between Aβ+ and Aβ- VCD group.DISCUSSION: Comorbid Aβ pathology affects the manifestation of VCD, but effects differ by severity of VCD.",

keywords = "Amyloid-β, Cognition, Gray matter atrophy, MRI, Vascular cognitive disorders, Vascular dementia, White matter hyperintensities",

author = "Leijenaar, {Jolien F} and Colin Groot and Sudre, {Carole H} and David Bergeron and Leeuwis, {Anna E} and Cardoso, {M Jorge} and Carrasco, {Ferran Prados} and Robert Laforce and Frederik Barkhof and {van der Flier}, {Wiesje M} and Philip Scheltens and Prins, {Niels D} and Rik Ossenkoppele",

year = "2020",

month = feb,

day = "1",

doi = "https://doi.org/10.1016/j.jalz.2019.08.190",

language = "English",

volume = "16",

pages = "354--364",

journal = "Alzheimers & Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Comorbid amyloid-β pathology affects clinical and imaging features in VCD

AU - Leijenaar, Jolien F

AU - Groot, Colin

AU - Sudre, Carole H

AU - Bergeron, David

AU - Leeuwis, Anna E

AU - Cardoso, M Jorge

AU - Carrasco, Ferran Prados

AU - Laforce, Robert

AU - Barkhof, Frederik

AU - van der Flier, Wiesje M

AU - Scheltens, Philip

AU - Prins, Niels D

AU - Ossenkoppele, Rik

PY - 2020/2/1

Y1 - 2020/2/1

N2 - INTRODUCTION: To date, the clinical relevance of comorbid amyloid-β (Aβ) pathology in patients with vascular cognitive disorders (VCD) is largely unknown.METHODS: We included 218 VCD patients with available cerebrospinal fluid Aβ42 levels. Patients were divided into Aβ+ mild-VCD (n = 84), Aβ- mild-VCD (n = 68), Aβ+ major-VCD (n = 31), and Aβ- major-VCD (n = 35). We measured depression with the Geriatric Depression Scale, cognition with a neuropsychological test battery and derived white matter hyperintensities (WMH) and gray matter atrophy from MRI.RESULTS: Aβ- patients showed more depressive symptoms than Aβ+. In the major-VCD group, Aβ- patients performed worse on attention (P = .02) and executive functioning (P = .008) than Aβ+. We found no cognitive differences in patients with mild VCD. In the mild-VCD group, Aβ- patients had more WMH than Aβ+ patients, whereas conversely, in the major-VCD group, Aβ+ patients had more WMH. Atrophy patterns did not differ between Aβ+ and Aβ- VCD group.DISCUSSION: Comorbid Aβ pathology affects the manifestation of VCD, but effects differ by severity of VCD.

AB - INTRODUCTION: To date, the clinical relevance of comorbid amyloid-β (Aβ) pathology in patients with vascular cognitive disorders (VCD) is largely unknown.METHODS: We included 218 VCD patients with available cerebrospinal fluid Aβ42 levels. Patients were divided into Aβ+ mild-VCD (n = 84), Aβ- mild-VCD (n = 68), Aβ+ major-VCD (n = 31), and Aβ- major-VCD (n = 35). We measured depression with the Geriatric Depression Scale, cognition with a neuropsychological test battery and derived white matter hyperintensities (WMH) and gray matter atrophy from MRI.RESULTS: Aβ- patients showed more depressive symptoms than Aβ+. In the major-VCD group, Aβ- patients performed worse on attention (P = .02) and executive functioning (P = .008) than Aβ+. We found no cognitive differences in patients with mild VCD. In the mild-VCD group, Aβ- patients had more WMH than Aβ+ patients, whereas conversely, in the major-VCD group, Aβ+ patients had more WMH. Atrophy patterns did not differ between Aβ+ and Aβ- VCD group.DISCUSSION: Comorbid Aβ pathology affects the manifestation of VCD, but effects differ by severity of VCD.

KW - Amyloid-β

KW - Cognition

KW - Gray matter atrophy

KW - MRI

KW - Vascular cognitive disorders

KW - Vascular dementia

KW - White matter hyperintensities

UR - http://www.scopus.com/inward/record.url?scp=85075884847&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jalz.2019.08.190

DO - https://doi.org/10.1016/j.jalz.2019.08.190

M3 - Article

C2 - 31786129

SN - 1552-5260

VL - 16

SP - 354

EP - 364

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

IS - 2

ER -

Comorbid amyloid-β pathology affects clinical and imaging features in VCD

Abstract

Keywords

Access to Document

Other files and links

Cite this